Pay in 4 interest-free payments of $10.50 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
A significant reduction of PCSK9 promoter activity by Anacetrapib (ANA) is detected at 3 µM concentration (−22%
Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders
Application of mitochondrial pyruvate carrier blocker UK5099 creates metabolic reprogram and greater stem-like properties in LnCap prostate cancer cells in vitro
A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity
KN-62 - CAS# 127191-97-3 Catalog No.:M6569-10 A significant reduction of PCSK9KN62, CAS No. 127191 97 3, is a P2X7R antagonist (hP2X7 IC50 = 51 nM) and Ca2+ calmodulin dependent protein kinase II inhibitor. KN62 inhibits the invasiveness of cancer cells in vitro and in vivo KN62 causes retrograde amnesia in the rat. KN62 attenuates glutamate release by inhibiting voltage dependent Ca(2+) channels. The effect of KN62 on Ca(2+) influx appears to be specific to slowly or non inactivating conductances, and therefore presents KN62
US$ 44.60
US$ 34.99
US$ 19.00
US$ 41.60
US$ 230.50
US$ 39.00
US$ 19.00